Solu-cortef and Bleeding disorders - a phase IV clinical study of FDA data

Summary:

Bleeding disorders is reported as a side effect among people who take Solu-cortef (hydrocortisone sodium succinate), especially for people who are male, 50-59 old, have been taking the drug for < 1 month also take Hydrocortisone, and have Hypercalcaemia of malignancy.

The phase IV clinical study analyzes which people have Bleeding disorders when taking Solu-cortef. It is created by eHealthMe based on reports of 7,966 people who have side effects when taking Solu-cortef from the FDA, and is updated regularly.

What is Solu-cortef?

Solu-cortef has active ingredients of hydrocortisone sodium succinate. eHealthMe is studying from 7,983 Solu-cortef users. Check the latest studies of Solu-cortef.

What is Bleeding disorders?

Bleeding disorders is found to be associated with 1,197 drugs and 1,648 conditions by eHealthMe. Check the latest studies of Bleeding disorders.

On Jul, 12, 2026

7,966 people reported to have side effects when taking Solu-cortef.
Among them, 32 people (0.4%) have Bleeding disorders.

Could Solu-cortef cause Bleeding disorders?

Among these 32 people:

How long have people been on Solu-cortef when they have Bleeding disorders? *

What is the gender of people who have Bleeding disorders when taking Solu-cortef? *

female: 50 %
male: 50 %

What is the age of people who have Bleeding disorders when taking Solu-cortef? *

What are other drugs people take besides Solu-cortef? *

What are other side effects people have besides Bleeding disorders? *

Pleural Effusion (water on the lungs): 18 people, 56.25%
Hypotension (abnormally low blood pressure): 18 people, 56.25%
Sepsis (a severe blood infection that can lead to organ failure and death): 18 people, 56.25%
Thrombocytopenia (decrease of platelets in blood): 16 people, 50.00%
Purulent Discharge (discharge that contains pus): 13 people, 40.62%
Lymph Follicular Hypertrophy (an increase in the size of the lymph node follicles): 13 people, 40.62%
Malnutrition (a condition that results from eating a diet in which certain nutrients are lacking): 13 people, 40.62%
Chronic Renal Failure (kidney failure): 13 people, 40.62%
Head Injury: 13 people, 40.62%
Cardiac Failure Congestive: 13 people, 40.62%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 11 people, 34.38%
Hypercalcaemia Of Malignancy (elevated calcium (ca+) level in the blood with cancer): 11 people, 34.38%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 6 people, 18.75%
Hypotension (abnormally low blood pressure): 3 people, 9.38%
Burkitt Lymphoma (cancer of the lymphatic system): 3 people, 9.38%
Fungal Infection: 3 people, 9.38%
Herpes Virus Infection: 3 people, 9.38%
Type 2 Diabetes: 2 people, 6.25%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 2 people, 6.25%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 2 people, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Solu-cortef and have Bleeding disorders?

- Check whether Bleeding disorders is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Solu-cortef:

Solu-cortef (7,983 reports)

Bleeding disorders treatments and more:

Bleeding disorders (24,450 reports)

How severe was Bleeding disorders and when was it recovered:

Bleeding disorders in Solu-cortef

Expand to all the drugs that have ingredients of hydrocortisone sodium succinate:

Bleeding disorders and drugs with ingredients of hydrocortisone sodium succinate

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Solu-cortef:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bleeding disorders:

Bleeding disorders (1,197 drugs)

Browse all the conditions that are associated with Bleeding disorders:

Bleeding disorders (1,648 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on hydrocortisone sodium succinate (the active ingredients of Solu-cortef) and Solu-cortef (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.